Ardea Biosciences, Inc., a biotechnology company, focuses on the discovery and development of small-molecule therapeutics for the treatment of gout, human immunodeficiency virus (HIV), and cancer in the United States. The companys products include RDEA594, a Phase IIb clinical trial product for the treatment of gout; RDEA684, a preclinical trial product for the treatment of gout with hyperuricemia; RDEA806, a non-nucleoside reverse transcriptase inhibitor, which completed Phase II clinical trial for the treatment of patients with HIV; and RDEA427, which is in first-in-human micro-dose pharmacokinetic study for the treatment of HIV infection. It is evaluating RDEA119, an inhibitor of Mitogen-activated ERK kinase (MEK), which is in Phase I/II study in combination with sorafenib and as a single agent in a Phase I study, both in advanced cancer patients. The company has a license agreement with Bayer to develop and commercialize MEK inhibitors for various indications. Ardea Biosciences, Inc. is based in San Diego, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• No BuyIns.Net Alerts Available for RDEA